@cp-neuron.bsky.social

Thank you Mikhail

The cell type risk genes we identified were mostly disease specific indicating unique vascular and immune mechanisms across these pathologies. Lastly, we integrated gene expression analysis to prioritise repurposable drugs with genetic evidence for the treatment of AD.

Using nanoCUT&Tag epigenomic profiling and pcHiC chromatin conformation analysis we found AD genetic risk is mostly immune with some vascular enrichment, whereas small vessel disease, which is often comorbid with AD, is strongly enriched for blood vessel cell types.

And a big thank you to both the examiners, Prof Mike Johnson and Dr Lasse Sinkkonen.

Thank you Hyejun!

Many thanks to the excellent team on this, including @kittybmurphy.bsky.social , Yuqian Ye, Maria Tsalenchuk and @nottalexi.bsky.social 🙏🏻🙏🏻

@sj-marzi.bsky.social @annamallach.bsky.social @andreaserio.bsky.social

Massive congrats and gratitude to lead authors Leyla Abbasova, Paulina Urbanaviciute, Di Hu and Joy Ismail, as well as collaborators Brian Schilder, @nottalexi.bsky.social and Nathan Skene 🙏🏻🥰 It's been a long journey, but I'm so glad I got to share it with these excellent colleagues!

We are missing you already!

Big congrats!

Special thanks to @kevincziegler.bsky.social, Tomas Solomon, Isidora Gocmanac and everyone who helped put the evening together!